Immupharma PLC Notice of AGM & Annual Report & Accounts (4784N)
June 01 2022 - 1:01AM
UK Regulatory
TIDMIMM
RNS Number : 4784N
Immupharma PLC
01 June 2022
RNS: RELEASE 1 JUNE 2022
ImmuPharma PLC
("ImmuPharma" or the "Company")
Notice of AGM & Annual Report & Accounts
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and
development company, confirms that the Notice of Annual General
Meeting ("AGM") has been posted to shareholders. The Annual Report
and Accounts for the year ended 31 December 2021 will be posted to
shareholders on 6 June 2022.
These documents will be available shortly, in electronic form,
for download on the Company's website www.immupharma.co.uk .
ImmuPharma's AGM will be held on Tuesday 28 June 2022 @ 10.30am
(BST) at: One Bartholomew Close, London, EC1A 7BL.
Ends
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman and Chief Executive + 44 (0) 207 206 2650
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes, Bob Pountney +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical
company that discovers and develops peptide-based therapeutics. The
Company's portfolio includes novel peptide therapeutics for
autoimmune diseases, metabolic diseases, anti-infectives and
cancer. The lead program, Lupuzor(TM), is a first-in class
autophagy immunomodulator which is in Phase 3 for the treatment of
lupus and preclinical analysis suggest therapeutic activity for
many other autoimmune diseases that share the same autophagy
mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on
28 November 2019, an exclusive licence and development agreement
and trademark agreement for Lupuzor(TM) to fund a new international
Phase 3 trial for Lupuzor(TM) and commercialise in the US.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSFLFLAEDILVIF
(END) Dow Jones Newswires
June 01, 2022 02:01 ET (06:01 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024